Outcomes of six-dose high-dose cytarabine (HiDAC-6) as a salvage regimen for patients with relapsed/refractory acute myeloid leukemia (RR-AML).

被引：1
|
作者：
Veltri, Lauren Westfall [1 ]
Anders, Brandi [1 ]
Kanate, Abraham Sebastian [1 ]
Shillingburg, Alexandra [1 ]
Craig, Michael D. [1 ]
Cumpston, Aaron [1 ]
机构：
[1] West Virginia Univ, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e18508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18508
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG
    Fiegl, M.
    Unterhalt, M.
    Kern, W.
    Braess, J.
    Spiekermann, K.
    Staib, P.
    Grueneisen, A.
    Woermann, B.
    Schoendube, D.
    Serve, H.
    Reichle, A.
    Hentrich, M.
    Schiel, X.
    Sauerland, C.
    Heinecke, A.
    Rieger, C.
    Beelen, D.
    Berdel, W. E.
    Buechner, T.
    Hiddemann, W.
    LEUKEMIA, 2014, 28 (05) : 1001 - 1007
  • [32] Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)
    Karimi, Yasmin H.
    Jain, Nitin
    Green, Margaret
    Godley, Lucy A.
    Weiner, Howie Lawrence
    Malnassy, Gregory
    Fulton, Noreen
    Artz, Andrew
    Liu, Hongtao
    Thirman, Michael J.
    Daunov, Michael
    Larson, Richard A.
    Stock, Wendy
    Odenike, Olatoyosi
    BLOOD, 2015, 126 (23)
  • [33] Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy
    Kam, Grace
    Yiu, Richard
    Loh, Yvonne
    Ang, Ai Leen
    Yueh, Ling Ling
    Goh, Yeow Tee
    Wong, Gee Chuan
    SUPPORTIVE CARE IN CANCER, 2015, 23 (03) : 643 - 649
  • [34] Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy
    Grace Kam
    Richard Yiu
    Yvonne Loh
    Ai Leen Ang
    Ling Ling Yueh
    Yeow Tee Goh
    Gee Chuan Wong
    Supportive Care in Cancer, 2015, 23 : 643 - 649
  • [35] IDARUBICIN AND HIGH-DOSE CYTARABINE IN THE TREATMENT OF REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA
    GIONA, F
    TESTI, AM
    AMADORI, S
    MELONI, G
    CAROTENUTO, M
    RESEGOTTI, L
    COLELLA, R
    LEONI, P
    CARELLA, AM
    GROTTO, P
    MINIERO, R
    MANDELLI, F
    ANNALS OF ONCOLOGY, 1990, 1 (01) : 51 - 55
  • [36] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
    Ramanathan, Muthalagu
    Cerny, Jan
    Raffel, Glen
    Walsh, William Vincent
    Woda, Bruce
    Miron, Patricia
    Nath, Rajneesh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).
    Larson, Sarah
    Campbell, Nicholas
    Huo, Dezheng
    Artz, Andrew
    Zhang, Yanming
    Gajria, Devika
    Green, Margaret
    Rahimova, Gamar
    Weiner, Howard
    Torres, Monica
    Odenike, Olatoyosi
    Godley, Lucy A.
    Rich, Elizabeth Shima
    Thirman, Michael
    Larson, Richard A.
    Stock, Wendy
    BLOOD, 2009, 114 (22) : 434 - 434
  • [38] Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?
    Bertoli, Sarah
    Gadaud, Noemie
    Tavitian, Suzanne
    Sarry, Audrey
    Berard, Emilie
    Huguet, Francoise
    Recher, Christian
    BLOOD, 2016, 128 (22)
  • [39] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
    Christian, Sonia
    Arain, Saad
    Patel, Pritesh
    Khan, Irum
    Calip, Gregory S.
    Agrawal, Vaibhav
    Sweiss, Karen
    Griffin, Shawn
    Cahill, Kirk
    Konig, Heiko
    Esen, Aysenur
    Shergill, Ardaman
    Odenike, Olatoyosi
    Stock, Wendy
    Quigley, John G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943
  • [40] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
12345